Skip to main content

ETHNOS_APP

Home • Search • Journals • List 0

Comparison of Carbapenem vs. Amikacin Antimicrobial Therapy for Pediatric Acute Pyelonephritis Caused by Extended-Spectrum Β-Lactamase-Positive Enterobacteriaceae

Bibliographic Data

ID15718792
AuthorsBurcu Ceylan Cura Yayla (0000-0001-5153-2136, Ministry of Health, corresponding author), Tuğba Bedir Demirdağ (0000-0002-6341-1849, Gazi University), Anıl Tapısız (0000-0002-6897-8297, Gazi University), Yeşim Özdemir Atikel (0000-0001-5304-3125, Eskişehir City Hospital), Hasan Tezer (0000-0001-6871-4112, Gazi University), Elif Ayça ŞAHİN (0000-0002-2215-2756, Gazi University), Kayhan Çağlar (0000-0001-7257-6453, Gazi University), Sevcan A Bakkaloğlu (0000-0001-6530-9672, Gazi University), Necla Buyan (0000-0003-3220-8335, Gazi University)
Year2025
Volume12
Issue7
Pages945-945
Publication date2025-07-18
Open AccessYes
TypeARTICLE
VenueChildren (JOURNAL)
Journal identifiersISSN: 2227-9067 • E-ISSN: 2227-9067
PublisherMultidisciplinary Digital Publishing Institute (PUBLISHER • CH)
DOI10.3390/children12070945
PMID40723138
OpenAlexW4412726236
LanguageEN
References cited26

Objectives : Acute pyelonephritis (APN) caused by extended-spectrum β-lactamase (ESBL)-positive Enterobacteriaceae poses a growing therapeutic challenge in children, as carbapenems remain the mainstay of treatment even when susceptibility to alternative agents such as amikacin is demonstrated. However, the widespread and inappropriate use of carbapenems can lead to carbapenem resistance. The aim of this study was to compare the clinical efficacy of amikacin and carbapenems in the management of pediatric acute pyelonephritis caused by ESBL-positive Enterobacteriaceae. Methods : We analyzed cases of pediatric acute pyelonephritis caused by ESBL-positive Enterobacteriaceae that were treated with either carbapenems or amikacin over a two-year period. This study compared microbiological cure, clinical improvement, and recurrence rates across the amikacin and carbapenem treatment groups. Results : Fifty-five patients were evaluated. The median age of the patients was 3 years (range, 0.1-13 years). The causative agents were E. coli in 43 cases (78.2%) and Klebsiella spp. in 12 cases (21.8%). All were susceptible to both carbapenem and amikacin in vitro. Twenty patients (36.3%) received a carbapenem and thirty-five (63.7%) received amikacin. Twenty-four (43.6%) had an underlying urological disease. No difference was observed between the groups in terms of microbiological cure, clinical improvement, or recurrence rates. Conclusions : Amikacin may be a potential alternative to carbapenems for treating pediatric ESBL-positive APN when in vitro susceptibility is confirmed

Amikacin · Antibiotics · Antimicrobial · Beta-lactamase · Biology · Carbapenem · Carbapenem-resistant enterobacteriaceae · Cephalosporin · Enterobacteriaceae · Escherichia coli · Intensive care medicine · Escherichia coli research studies · Medicine · Pediatric Urology and Nephrology Studies · Urinary Tract Infections Management · Internal Medicine · Microbiology

Highly citedNo

Tools

Open DOIOpen Access
Ethnos_APP • Open Source Project • MIT License • Frontend v2.0.0 • Privacy and Cookies • API Documentation: api.ethnos.app/docs • API Source Code: GitHub • DOI: 10.5281/zenodo.17049435 • Frontend Source Code: GitHub • DOI: 10.5281/zenodo.17050053 • cruz.rio.br • Expectantes Misericordiae